ObjectiveTo evaluate the safety and efficacy of preoperation administration of enteral nutrition enriched ω-3 fatty acids for gastric cancer patients. MethodsA single center randomized controlled clinical trial was performed in 60 cases of gastric cancer in West China Hospital during January 2014 to June 2014, and cases were equally randomized divided into treatment group and control group. Cases of treatment group were given enteral nutrition enriched ω-3 fatty acids which was manufactured by Fresenius Kabi Deutschland GmbH for 5 consecutive days before operation, and cases of control group were given an isocaloric and isonitrogenous homogenized diet for 5 consecutive days before operation. The laboratory indexes of nutritional status and imflammatory factors were observed and compared between 2 groups on admission, preoperative day 1, postoperative day 3, and postoperative day 5. Liver and kidney function indexes which as the safety indexes were detected on admission and preoperative day 1. Vomiting, diarrhea, and infectious complications were recorded in addition. ResultsOn 3 days after operation, levels of interleukin-6 (IL-6) and α-acid glycoprotein (AAG) of treatment group were both lower than those of control group (P<0.05); on 5 days after operation, levels of C-reactive protein (CRP) of treatment group was lower than that of control group too (P<0.05); but at other time points, there were no significant differences in any index between the 2 groups (P>0.05). During the period of enteral nutrition, only 1 case suffered from bloating and 1 case suffered from diarrhea, both in treatment group, and the incidence of adverse reactions didn't differed between treatment group[6.7% (2/30)]and control group[0 (0/30)], P>0.05. Moreover, there were no significant differences between treatment group and control group in incidences of wound infection[3.3% (1/30) vs. 10.0% (3/30)], abdominal infection[0 (0/30) vs. 3.3% (1/30)], urinary infection[0 (0/30) vs. 3.3% (1/30)], and pulmonary infection[0 (0/30) vs. 6.7% (2/30)], but the total incidence of complication was lower in treatment group than that of control group[3.3% (1/30) vs. 23.3% (7/30)], P=0.026. ConclusionEnteral nutrition enriched ω-3 fatty acids can reduce the rate of infection-related complication for patients with gastric cancer, and has a sense of safety.
ObjectiveTo quantitate expression of miR21 in rectal cancer of different tumor stages and discuss their significances. MethodThe expression of miR21 was detected and quantitated in the rectal cancer tissues and corresponding adjacent normal tissues of 40 patients with rectal cancer in this hospital from August 2012 to October 2012 by Taq Man microRNA assay. ResultsThe significant overexpression of miR21 was observed in the rectal cancer tissues (4.122±1.973 versus 1.825±0.661, P=0.000)as compared with the corresponding adjacent normal tissues. The expressions of miR21 in the rectal cancer tissues of N1-N2 and Dukes C-D stages were significantly higher than those in the rectal cancer tissues of N0(4.852±2.344 versus 3.391±1.171, P=0.019)and Dukes A-B stage(4.787±2.304 versus 3.386±1.203, P=0.021). From N0 to N2 stage, the expression of miR21 increased progressively in the rectal cancer, and the expression in the rectal cancer tissues of N2 stage was significantly higher than that in the N0 stage(5.556±1.500 versus 3.391±1.171, P=0.010). And receiver operating characteristics curve analysis showed that miR21 could discriminate N 0 stage from N1-N2 stage with a 0.698 area under curve(AUC), 50.0% sensitivity and 90.0% specificity, Dukes C-D stage from A-B stage with a 0.689 AUC, 42.9% sensitivity and 94.7% specificity. ConclusionmiR21 appears to have a potential correlation with N and Dukes stages of rectal cancer, which cautiously and optimistically suggests that it could be a potential novel biomarker for predicting tumor stage preoperatively.